- ARNA has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $10.9 million.
- ARNA has traded 428,525 shares today.
- ARNA is trading at 2.80 times the normal volume for the stock at this time of day.
- ARNA is trading at a new high 3.02% above yesterday's close.
'Strong on High Relative Volume' stocks are worth watching because major volume moves tend to indicate underlying activity such as M&A events, material stock news, analyst upgrades, insider buying, buying from 'superinvestors,' or that hedge funds and momentum traders are piling into a stock ahead of a catalyst. Regardless of the impetus behind the price and volume action, when a stock moves with strength and volume it can indicate the start of a new trend on which early investors can capitalize. In the event of a well-timed trading opportunity, combining technical indicators with fundamental trends and a disciplined trading methodology should help you take the first steps towards investment success. EXCLUSIVE OFFER: Get the inside scoop on opportunities in ARNA with the Ticky from Trade-Ideas. See the FREE profile for ARNA NOW at Trade-Ideas More details on ARNA:
Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors. The company offers BELVIQ, a drug used to treat chronic weight management in adults. Currently there are 2 analysts that rate Arena Pharmaceuticals a buy, 1 analyst rates it a sell, and 3 rate it a hold.The average volume for Arena Pharmaceuticals has been 2.7 million shares per day over the past 30 days. Arena has a market cap of $1.1 billion and is part of the health care sector and drugs industry. The stock has a beta of 0.33 and a short float of 14.5% with 12.53 days to cover. Shares are up 26.5% year-to-date as of the close of trading on Monday. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE. TheStreetRatings.com Analysis: TheStreet Quant Ratings rates Arena Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, weak operating cash flow, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Highlights from the ratings report include:
- Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Biotechnology industry and the overall market, ARENA PHARMACEUTICALS INC's return on equity significantly trails that of both the industry average and the S&P 500.
- Net operating cash flow has decreased to -$23.02 million or 20.40% when compared to the same quarter last year. In addition, when comparing to the industry average, the firm's growth rate is much lower.
- ARNA's stock share price has done very poorly compared to where it was a year ago: Despite any rallies, the net result is that it is down by 26.37%, which is also worse that the performance of the S&P 500 Index. Investors have so far failed to pay much attention to the earnings improvements the company has managed to achieve over the last quarter. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.
- ARENA PHARMACEUTICALS INC has improved earnings per share by 16.7% in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. We feel it is likely to report a decline in earnings in the coming year. During the past fiscal year, ARENA PHARMACEUTICALS INC reported poor results of -$0.29 versus -$0.10 in the prior year. For the next year, the market is expecting a contraction of 81.0% in earnings (-$0.53 versus -$0.29).
- The company, on the basis of net income growth from the same quarter one year ago, has significantly underperformed compared to the Biotechnology industry average, but is greater than that of the S&P 500. The net income increased by 3.8% when compared to the same quarter one year prior, going from -$25.26 million to -$24.30 million.
- You can view the full Arena Pharmaceuticals Ratings Report.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.